Teva Coreg Damages Reinstated As AAM Bemoans ‘Antithetical’ Ruling
Israeli Firm Is On Hook Again For $235m Payment
Teva has once again been instructed to compensate GSK with $235m in damages after a split US Court of Appeals reversed a lower court finding that Teva had not willfully induced infringement of a method-of-use patent shielding the originator’s Coreg antihypertensive.
You may also be interested in...
Federal Circuit panel to reconsider whether Teva induced infringement of GSK Coreg patent despite label carve-out. Biologics and biosimilars could be particularly hurt if ruling stands given FDA’s recent guidance requiring reference to branded product.
A controversial ruling that threatens so-called “skinny label” carve-outs of patented indications by US generics will be re-examined by the Court of Appeals for the Federal Circuit, following a petition by Teva.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.